1. Cell Biology

LRG1 is an adipokine that promotes insulin sensitivity and suppresses inflammation

  1. Chan Hee J Choi
  2. William Barr
  3. Samir Zaman
  4. Corey Model
  5. Annsea Park
  6. Mascha Koenen
  7. Zeran Lin
  8. Sarah K Szwed
  9. François Marchildon
  10. Audrey Crane
  11. Thomas S Carroll
  12. Henrik Molina
  13. Paul Cohen  Is a corresponding author
  1. Rockefeller University, United States
  2. Yale University, United States
https://doi.org/10.7554/eLife.81559
Share this article
Cite this article
  1. Chan Hee J Choi
  2. William Barr
  3. Samir Zaman
  4. Corey Model
  5. Annsea Park
  6. Mascha Koenen
  7. Zeran Lin
  8. Sarah K Szwed
  9. François Marchildon
  10. Audrey Crane
  11. Thomas S Carroll
  12. Henrik Molina
  13. Paul Cohen
(2022)
LRG1 is an adipokine that promotes insulin sensitivity and suppresses inflammation
eLife 11:e81559.
https://doi.org/10.7554/eLife.81559
  2. Download BibTeX
  3. Download .RIS

Abstract

While dysregulation of adipocyte endocrine function plays a central role in obesity and its complications, the vast majority of adipokines remain uncharacterized. We employed bio-orthogonal non-canonical amino acid tagging (BONCAT) and mass spectrometry to comprehensively characterize the secretome of murine visceral and subcutaneous white and interscapular brown adipocytes. Over 600 proteins were identified, the majority of which showed cell type-specific enrichment. We here describe a metabolic role for leucine-rich α-2 glycoprotein 1 (LRG1) as an obesity-regulated adipokine secreted by mature adipocytes. LRG1 overexpression significantly improved glucose homeostasis in diet-induced and genetically obese mice. This was associated with markedly reduced white adipose tissue macrophage accumulation and systemic inflammation. Mechanistically, we found LRG1 binds cytochrome c in circulation to dampen its pro-inflammatory effect. These data support a new role for LRG1 as an insulin sensitizer with therapeutic potential given its immunomodulatory function at the nexus of obesity, inflammation, and associated pathology.

Data availability

Proteomic dataset has been deposited to Proteomexchange PRIDE under accession PXD035318. RNA-Seq data have been deposited to GEO under accession GSE208219. All original gels and blots are available as Source Data Files.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Chan Hee J Choi

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  2. William Barr

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  3. Samir Zaman

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  4. Corey Model

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  5. Annsea Park

    Department of Immunobiology, Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.

  6. Mascha Koenen

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1024-4506

  7. Zeran Lin

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4418-2443

  8. Sarah K Szwed

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  9. François Marchildon

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  10. Audrey Crane

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  11. Thomas S Carroll

    Bioinformatics Resouce Center, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.

  12. Henrik Molina

    Proteomics Resource Center, Rockefeller University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8950-4990

  13. Paul Cohen

    Laboratory of Molecular Metabolism, Rockefeller University, New York, United States
    For correspondence
    pcohen@rockefeller.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2786-8585

Funding

American Diabetes Association (1-17-ACE-17)

  • Paul Cohen

National Institutes of Health (RC2 DK129961)

  • Paul Cohen

National Institute of General Medical Sciences (T32GM007739)

  • Chan Hee J Choi
  • Sarah K Szwed

Sarnoff Cardiovascular Research Foundation

  • Samir Zaman

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal studies were performed in accordance with the institutional guidelines of the Rockefeller University Institutional Animal Care and Use Committee (IACUC) protocol (18016-H). Experiments involving adenoviral and AAV8 vectors were performed under general anesthesia using isoflurane, in accordance with the institutional ABSL-2 guidelines.

Copyright

© 2022, Choi et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,617
    views
  • 525
    downloads
  • 14
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Chan Hee J Choi
  2. William Barr
  3. Samir Zaman
  4. Corey Model
  5. Annsea Park
  6. Mascha Koenen
  7. Zeran Lin
  8. Sarah K Szwed
  9. François Marchildon
  10. Audrey Crane
  11. Thomas S Carroll
  12. Henrik Molina
  13. Paul Cohen
(2022)
LRG1 is an adipokine that promotes insulin sensitivity and suppresses inflammation
eLife 11:e81559.
https://doi.org/10.7554/eLife.81559

Share this article

https://doi.org/10.7554/eLife.81559

Categories and tags

Research organism

Further reading

    1. Cell Biology

    Small-molecule activation of TFEB alleviates Niemann–Pick disease type C via promoting lysosomal exocytosis and biogenesis

    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.

    1. Cell Biology

    Stratification of enterochromaffin cells by single-cell expression analysis

    Yan Song, Linda J Fothergill ... Gene W Yeo
    Research Article

    Dynamic interactions between gut mucosal cells and the external environment are essential to maintain gut homeostasis. Enterochromaffin (EC) cells transduce both chemical and mechanical signals and produce 5-hydroxytryptamine to mediate disparate physiological responses. However, the molecular and cellular basis for functional diversity of ECs remains to be adequately defined. Here, we integrated single-cell transcriptomics with spatial image analysis to identify 14 EC clusters that are topographically organized along the gut. Subtypes predicted to be sensitive to the chemical environment and mechanical forces were identified that express distinct transcription factors and hormones. A Piezo2+ population in the distal colon was endowed with a distinctive neuronal signature. Using a combination of genetic, chemogenetic, and pharmacological approaches, we demonstrated Piezo2+ ECs are required for normal colon motility. Our study constructs a molecular map for ECs and offers a framework for deconvoluting EC cells with pleiotropic functions.

    1. Cell Biology
    2. Developmental Biology

    Lens Development: Bringing signaling complexity into focus

    Sarah Y Coomson, Salil A Lachke
    Insight

    A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.